Newport News, Virginia – Tidewater Physicians Multispecialty Group (TPMG), a network of over 240 physicians and advanced care providers in over 85 locations across the Tidewater area, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Akebia pharmaceutical’s Vafseo® (vadadustat) tablets, a drug used for the treatment of anemia from chronic kidney disease (CKD) in adults on dialysis. Beginning in February 2019, the TPMG Clinical Research Division in Newport News conducted clinical trials for this drug to test the efficacy of stimulating the body’s physiologic response to achieve and sustain target Hb levels. “We are proud to have contributed to this important advance in the care of people with chronic kidney disease on dialysis,” said TPMG Clinical Research Director, Linda G.P. Schneider, MD. Anemia is a common issue encountered by individuals undergoing dialysis for the treatment of CKD. According to the Centers for Disease Control and Prevention(CDC), more than 37 million Americans may be affected by CKD, and it is estimated that one in seven kidney disease patients also suffer from anemia. The majority of currently approved treatments for CKD-related anemia must be administered as an injection at dialysis centers. Vafseo® (vadadustat) tablets are an oral therapy that is easier and more accessible for CKD patients undergoing home dialysis. To learn more about Vafseo® (vadadustat) tablets’ recent approval, visit:
|
|